An official website of the United States government
In the United States, over 100,000 women are diagnosed with a gynecologic malignancy every year, with ovarian cancer being the most lethal. One of the hallmark characteristics of ovarian cancer is the development of resistance to chemotherapeutics. While the exact mechanisms of chemoresistance are poorly understood, it is known that changes at the cellular and molecular level make chemoresistance challenging to treat. Improved therapeutic options are needed to target these changes at the molecular level. Using a precision medicine approach, such as gene therapy, genes can be specifically exploited to resensitize tumors to therapeutics. This review highlights traditional and novel gene targets that can be used to develop new and improved targeted therapies, from drug efflux proteins to ovarian cancer stem cells. The review also addresses the clinical relevance and landscape of the discussed gene targets.
more »
« less
CANDI: a web server for predicting molecular targets and pathways of cannabis-based therapeutics
Abstract BackgroundCannabis sativaL. with a rich history of traditional medicinal use, has garnered significant attention in contemporary research for its potential therapeutic applications in various human diseases, including pain, inflammation, cancer, and osteoarthritis. However, the specific molecular targets and mechanisms underlying the synergistic effects of its diverse phytochemical constituents remain elusive. Understanding these mechanisms is crucial for developing targeted, effective cannabis-based therapies. MethodsTo investigate the molecular targets and pathways involved in the synergistic effects of cannabis compounds, we utilized DRIFT, a deep learning model that leverages attention-based neural networks to predict compound-target interactions. We considered both whole plant extracts and specific plant-based formulations. Predicted targets were then mapped to the Reactome pathway database to identify the biological processes affected. To facilitate the prediction of molecular targets and associated pathways for any user-specified cannabis formulation, we developed CANDI (Cannabis-derived compound Analysis and Network Discovery Interface), a web-based server. This platform offers a user-friendly interface for researchers and drug developers to explore the therapeutic potential of cannabis compounds. ResultsOur analysis using DRIFT and CANDI successfully identified numerous molecular targets of cannabis compounds, many of which are involved in pathways relevant to pain, inflammation, cancer, and other diseases. The CANDI server enables researchers to predict the molecular targets and affected pathways for any specific cannabis formulation, providing valuable insights for developing targeted therapies. ConclusionsBy combining computational approaches with knowledge of traditional cannabis use, we have developed the CANDI server, a tool that allows us to harness the therapeutic potential of cannabis compounds for the effective treatment of various disorders. By bridging traditional pharmaceutical development with cannabis-based medicine, we propose a novel approach for botanical-based treatment modalities.
more »
« less
- Award ID(s):
- 2210963
- PAR ID:
- 10630671
- Publisher / Repository:
- Journal of Cannabis Research
- Date Published:
- Journal Name:
- Journal of Cannabis Research
- Volume:
- 7
- Issue:
- 1
- ISSN:
- 2522-5782
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Lu, Zhiyong (Ed.)Abstract MotivationForecasting the synergistic effects of drug combinations facilitates drug discovery and development, especially regarding cancer therapeutics. While numerous computational methods have emerged, most of them fall short in fully modeling the relationships among clinical entities including drugs, cell lines, and diseases, which hampers their ability to generalize to drug combinations involving unseen drugs. These relationships are complex and multidimensional, requiring sophisticated modeling to capture nuanced interplay that can significantly influence therapeutic efficacy. ResultsWe present a novel deep hypergraph learning method named Heterogeneous Entity Representation for MEdicinal Synergy (HERMES) prediction to predict the synergistic effects of anti-cancer drugs. Heterogeneous data sources, including drug chemical structures, gene expression profiles, and disease clinical semantics, are integrated into hypergraph neural networks equipped with a gated residual mechanism to enhance high-order relationship modeling. HERMES demonstrates state-of-the-art performance on two benchmark datasets, significantly outperforming existing methods in predicting the synergistic effects of drug combinations, particularly in cases involving unseen drugs. Availability and implementationThe source code is available at https://github.com/Christina327/HERMES.more » « less
-
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered a global COVID-19 pandemic, challenging healthcare systems worldwide. Effective therapeutic strategies against this novel coronavirus remain limited, underscoring the urgent need for innovative approaches. The present research investigates the potential of cannabis compounds as therapeutic agents against SARS-CoV-2 through their interaction with the virus’s papain-like protease (PLpro) protein, a crucial element in viral replication and immune evasion. Computational methods, including molecular docking and molecular dynamics (MD) simulations, were employed to screen cannabis compounds against PLpro and analyze their binding mechanisms and interaction patterns. The results showed cannabinoids with binding affinities ranging from −6.1 kcal/mol to −4.6 kcal/mol, forming interactions with PLpro. Notably, Cannabigerolic and Cannabidiolic acids exhibited strong binding contacts with critical residues in PLpro’s active region, indicating their potential as viral replication inhibitors. MD simulations revealed the dynamic behavior of cannabinoid–PLpro complexes, highlighting stable binding conformations and conformational changes over time. These findings shed light on the mechanisms underlying cannabis interaction with SARS-CoV-2 PLpro, aiding in the rational design of antiviral therapies. Future research will focus on experimental validation, optimizing binding affinity and selectivity, and preclinical assessments to develop effective treatments against COVID-19.more » « less
-
The integration of single-cell genomics into the chemical genetics paradigm is reshaping how researchers profile drug activity, prioritize lead candidates, and uncover new therapeutic opportunities. Traditional chemical genetic approaches, though instrumental in linking compounds to cellular phenotypes, often rely on bulk measurements that obscure important cellular heterogeneity and limit insight into mechanisms of action. By contrast, single-cell technologies offer a transformative view of how compounds influence diverse cell types and states, capturing nuanced molecular responses that further our understanding of efficacy, resistance, and polypharmacology. From cancer to neurodegenerative disorders and other disease contexts, single-cell chemical profiling enables a more precise annotation of drug-induced effects, revealing differential responses across cellular subpopulations. These methods help identify both beneficial and adverse outcomes that may not be readily predicted by a compound’s structure or known targets, enhancing preclinical prioritization and supporting rational drug repurposing strategies. As these technologies mature, advances in multiplexing, multimodal profiling, and computational analysis are expanding their scalability and applicability to increasingly complex models. The resulting data-rich assays are poised to bridge critical gaps between compound screening and clinical relevance. This review highlights the evolution of chemical genomics toward single-cell resolution and outlines emerging opportunities to leverage these methods throughout the drug discovery pipeline, from early preclinical prioritization to late-stage repurposing, ultimately accelerating the development of safer, more effective therapies.more » « less
-
Abstract Drug resistance poses a significant challenge in cancer treatment. Despite the initial effectiveness of therapies such as chemotherapy, targeted therapy and immunotherapy, many patients eventually develop resistance. To gain deep insights into the underlying mechanisms, single-cell profiling has been performed to interrogate drug resistance at cell level. Herein, we have built the DRMref database (https://ccsm.uth.edu/DRMref/) to provide comprehensive characterization of drug resistance using single-cell data from drug treatment settings. The current version of DRMref includes 42 single-cell datasets from 30 studies, covering 382 samples, 13 major cancer types, 26 cancer subtypes, 35 treatment regimens and 42 drugs. All datasets in DRMref are browsable and searchable, with detailed annotations provided. Meanwhile, DRMref includes analyses of cellular composition, intratumoral heterogeneity, epithelial–mesenchymal transition, cell–cell interaction and differentially expressed genes in resistant cells. Notably, DRMref investigates the drug resistance mechanisms (e.g. Aberration of Drug’s Therapeutic Target, Drug Inactivation by Structure Modification, etc.) in resistant cells. Additional enrichment analysis of hallmark/KEGG (Kyoto Encyclopedia of Genes and Genomes)/GO (Gene Ontology) pathways, as well as the identification of microRNA, motif and transcription factors involved in resistant cells, is provided in DRMref for user’s exploration. Overall, DRMref serves as a unique single-cell-based resource for studying drug resistance, drug combination therapy and discovering novel drug targets.more » « less
- Free Publicly Accessible Full Text
-
Accepted Manuscript
- Journal Article:
- https://doi.org/10.1186/s42238-025-00268-w
